Beau Kilmer, Kristy Kruithof, Mafalda Pardal, Jonathan P. Caulkins, Jennifer Rubin
14 December 2013
This RAND report provides an overview of the changes to laws and policies pertaining to cannabis in different countries. Several jurisdictions have reduced the penalties for possessing cannabis for personal use (and in some places even for home cultivation), while some jurisdictions have taken more dramatic steps and changed their laws and practices with respect to producing and distributing cannabis.
On December 10, 2013, the General Assembly of Uruguay approved a law that made the country the first one in the world to fully regulate the cultivation, trade and consumption of cannabis for medical, industrial as well as recreational purposes. This infographic gives a short overview of the main aspects of the new law.
Uruguay's approval of regulation under state control marks a tipping point in the failed war against drugs as it makes Uruguay the first country in the world to fully regulate the cultivation, trade and consumption of cannabis for medical, industrial as well as recreational purposes. This infographic gives a quick summary of the reasons why Uruguay is regulating cannabis.
This is a guide to regulating legal markets for the non-medical use of cannabis. It is for policy makers, drug policy reform advocates and affected communities all over the world, who are witnessing the question change from, 'Should we maintain cannabis prohibition?' to 'How will legal regulation work in practice?
Emily Crick, Heather J. Haase, David Bewley-Taylor
14 November 2013
In November 2012, voters in two US states – Washington and Colorado – approved ballot initiatives to establish legally regulated markets for the production, sale, use and taxation of cannabis (commonly referred to in the US as marijuana). This is the first time anywhere in the world that the recreational use of the drug will be legally regulated – the wellknown coffee shop system in the Netherlands is merely tolerated rather than enshrined in law. Needless to say, with implications both within and beyond US borders, the drug policy community is watching Colorado and Washington closely.
The Transnational Institute (TNI) organized an expert seminar on Costs and Benefits of Cannabis Regulation Models in Europe in Amsterdam, The Netherlands on October 31/November 1, 2013. The objective of the seminar was to identify and map existing and possible future cannabis regulation models in Europe, looking at the local, provincial and national levels and the potential impact of such models on the illicit cannabis market.
On 11 July 2013, the New Zealand Parliament passed the Psychoactive Substances Act. The legislation enacted a new legal framework for the testing, manufacture, sale, and regulation of psychoactive products with the responsibility on manufacturers to prove a product 'low risk before it could be sold.' The expectation is that the adoption of new modern drug policies will ensure that the drugs people do take are safe, and that help can be accessed easily for those who need it. If the New Zealand approach is successful, other countries might follow lead, or even improve on what has been have done so far.
Three United Nations Conventions provide the international legal framework on drug control, instructing countries to limit drug supply and use to medical and scientific purposes. Yet, debate continues on the decriminalisation, or even legalisation, of drugs, particularly cannabis. Models under development for the legal supply of cannabis are described in this analysis, as well as some of the questions they raise.
Part of the ‘Perspectives on drugs’ (PODs) series, launched alongside the annual European Drug Report, these designed-for-the-web interactive analyses aim to provide deeper insights into a selection of important issues.
Latin America has emerged at the vanguard of efforts to promote debate on drug policy reform. For decades, Latin American governments largely followed the drug control policies and programs of Washington’s so-called war on drugs. Yet two parallel trends have resulted in a dramatic change in course: the emergence of left-wing governments that have challenged Washington’s historic patterns of unilateralism and interventionism and growing frustration with the failure of the prohibitionist drug control model put forward by the US government.
New psychoactive drugs (NPDs, new psychoactive substances) enter the market all the time. However, it takes several months to ban these NPDs and immediate action is generally not possible. Several European countries and drug enforcement officers insist on a faster procedure to ban NPDs. Introduction of generic legislation, in which clusters of psychotropic drugs are banned in advance, has been mentioned as a possible solution. Here we discuss the pros and cons of such an approach.
For forty years the Misuse of Drugs Act 1971 has formed the corner stone of drug policy in Britain. The emergence of new psychoactive substances (‘legal highs’) during the past fifteen years or so has challenged the drug control system. The arrival in 2012 of a new psychoactive substance on the market, on average, every six days raises questions about how best to protect young people from unknown and unsafe drugs. The Government is considering this challenge and we hope this Inquiry report will make a helpful contribution to their deliberations.